Qlaris Bio

Wellesley, United States

Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.

$24.0M raised

Apr 2024

Series B

Top Investors

Correlation VenturesCanaan PartnersAberdeenNew Leaf Venture PartnersMayo Clinic Ventures

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Qlaris Bio raised?

Qlaris Bio has raised $24.0M in total funding. The most recent round was Series B. The last funding was announced in April 2024.

Who are Qlaris Bio's investors?

Qlaris Bio's investors include Correlation Ventures, Canaan Partners, Aberdeen, New Leaf Venture Partners, Mayo Clinic Ventures.

Where is Qlaris Bio headquartered?

Qlaris Bio is headquartered in Wellesley, United States.

What does Qlaris Bio do?

Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.

What stage is Qlaris Bio at?

Qlaris Bio is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 22, 2024.

MLA

"Qlaris Bio — Funding & Investors." VCBacked, April 22, 2024, https://www.vcbacked.co/company/qlaris-bio. Accessed June 4, 2026.

APA

VCBacked. (2024). Qlaris Bio — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/qlaris-bio

Wikipedia (cite web)

{{cite web |title=Qlaris Bio — Funding & Investors |url=https://www.vcbacked.co/company/qlaris-bio |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 22, 2024.